Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Símbolo de cotizaciónINDV
Nombre de la empresaIndivior PLC
Fecha de salida a bolsaDec 24, 2014
Director ejecutivoMr. Joseph J. (Joe) Ciaffoni
Número de empleados1030
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 24
Dirección234 Bath Road
CiudadSLOUGH
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalSL1 4EE
Teléfono448043791090
Sitio Webhttps://www.indivior.com/en
Símbolo de cotizaciónINDV
Fecha de salida a bolsaDec 24, 2014
Director ejecutivoMr. Joseph J. (Joe) Ciaffoni
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos